SGN-35SGN-35 is in phase I clinical trials for relapsed or refractory Hodgkin lymphoma and other CD30-positive hematologic malignancies. Study details are available from the clinicaltrials.gov links below:
These trials are designed to evaluate the safety, pharmacokinetic profile and antitumor activity of SGN-35. If you or your physician have any questions about these clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Product Candidate Details SGN-35 is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody joined by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics’ proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into CD30-expressing tumor cells, resulting in a targeted cell-killing effect. About CD30-Positive Hematologic Malignancies Lymphoma is a general term for a group of cancers that originate in the lymphatic system. The lymphomas are divided into two major categories: Hodgkin lymphoma and all other lymphomas, or non-Hodgkin lymphomas. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen. According to the American Cancer Society, an estimated 8,200 cases of Hodgkin lymphoma will be diagnosed in the United States during 2008, and nearly 1,300 people would die of the disease. Approximately 66,000 new cases of non-Hodgkin lymphoma will be diagnosed in the United States during 2008 according to the American Cancer Society. An estimated 15 percent of non-Hodgkin lymphomas are of T-cell origin, many of which express CD30. |